Tag: closing

This new capital will accelerate the deployment of Nesto Cloud’s AI-powered lending platform across the mortgage financing and financial services sectors.

As previously announced today in a press release, Ascencio (the “Company”) has launched a capital increase in cash within the limits of the authorised capital via an accelerated bookbuilding process mainly with qualified investors, with a waiver of the preferential subscription rights of existing shareholders.

WARWICK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today announced Ballislife Drink Inc.’s entry into the Southern California market through Varon Corp’s U.S. subsidiary, Varon USA, supported by the appointment of Tenace Consulting (Tenace) as its regional distribution partner. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP.

ACHESON, Alberta, June 10, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG”) (TSX: NOA / NYSE: NOA) announced today that it has entered into an underwriting agreement to sell, pursuant to a private placement offering (the “Offering”), $200 million aggregate principal amount of 7.00% Senior Unsecured Notes due June 16, 2031 (the “Notes”). The Notes will be issued at a price of $1,000 per $1,000 of Notes. The Notes will accrue interest at the rate of 7.00% per annum, payable in cash in equal payments semi-annually in arrears each June 16 and December 16, commencing on December 16, 2026. The Notes will be issued pursuant to an indenture to be entered into between NACG and Computershare Trust Company of Canada, as trustee.

Key Takeaways

FORM 8.5 (EPT/RI)

Paris, June 10, 2026

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.